Celgene Bid To Ax FCA Suit Is Premature, US Says

Law360, New York (June 13, 2014, 5:29 PM ET) -- The U.S. government on Thursday weighed in on Celgene Corp.’s bid to nix a whistleblower’s False Claims Act suit in California federal court over alleged off-label drug promotions and kickbacks to doctors, arguing the drug company prematurely moved for dismissal and relied on faulty theories about what constitutes a false claim.



Although it has not intervened in the case, the government argued in a statement of interest that Celgene was wrong to claim the complaint should be axed for failing to allege that providers hadn't “certified”...

To view the full article, register now.